XPR1 and obesity disorder: The oral administration of UDCA recapitulated the anti-obesity effects and metabolic benefits of XA1416, functioning as an intestinal Farnesoid X receptor antagonist and Takeda G-protein-coupled receptor 5 agonist to stimulate GLP-1 secretion.